Article Sidebar

Submitted
8 September 2020
Published
1 June 2021
Download
PDF
Statistic
Read Counter : 930 Download : 825

Main Article Content

Abstract

Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Sutadji, J. C., Widodo, A. D. W., & Indiastuti, D. N. (2021). Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19. Folia Medica Indonesiana, 57(2), 158–165. https://doi.org/10.20473/fmi.v57i2.21929
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Antwi-Amoabeng D, Kanji Z, Ford B et al (2020). Clinical outcomes in covid-19 patients treated with tocilizumab: An individual patient data systematic review. Journal of Medical Virology. Available from https://onlinelibrary.wiley.com/doi/10.1002/jmv.26038. Accessed August 12, 2020
  2. Canziani LM, Trovati S, Brunetta E, et al (2020). Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of autoimmunity 114, 1-7.
  3. Capra R, De Rossi N, Mattioli F, et al (2020). Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European Journal of Internal Medicine 76, 31-35.
  4. CDC (2020). Coronavirus disease 2019 (COVID-19): Symptoms. centers for disease control and prevention. Available from https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed August 12, 2020
  5. Coperchini F, Chiovato L, Croce L, et al (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Reviews 53, 25-32.
  6. De Rossi N, Scarpazza C, Filippini C, et al (2020). Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. E-clinical Medicine 25, 1-9.
  7. Ge H, Wang X, Yuan X, et al (2020). The epidemiology and clinical information about COVID-19. European Journal of Clinical Microbiology & Infectious Diseases 39, 1011-1019.
  8. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al (2020). Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2, e474-e484.
  9. Klopfenstein T, Zayet S, Lohse A, et al (2020). Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International Journal of Infectious Diseases 99, 491-495.
  10. Klopfenstein T, Zayet S, Lohse A, et al (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Medecine et Maladies Infectieuses 50, 397-400.
  11. Li X, Geng M, Peng Y, et al (2020). Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis 10, 102-108.
  12. Liu B, Li M, Zhou Z, et al (2020). Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. Journal of Autoimmunity 111, 1-9.
  13. Luo P, Liu Y, Qiu L, et al (2020). Tocilizumab treatment in COVID-19: A single center experience. Journal of Medical Virology 92, 814-818.
  14. Moore JB, June CH (2020). Cytokine release syndrome in severe COVID-19. Science 368, 473-474.
  15. Rojas-Marte G, Khalid M, Mukhtar O, et al (2020). Outcomes in patients with severe COVID-19 disease treated with tocilizumab: A case-controlled study. QJM 113, 546-550.
  16. Tufan A, Avanoğlu GA, Matucci-Cerinic M (2020). Covid-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish Journal of Medical Sciences 50, 620-632.
  17. Zhou F, Yu T, Du R, et al (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395, 1054-1062.